Tempus Ai (TEM) traded up 5.96 % during a 24 hours period ending at 03:29 PM Central Europe on Monday 26th. One Tempus Ai stock can currently be bought for about USD 65.88 on popular exchanges. Current supply of Tempus Ai stocks is 177.2 mn. Tempus Ai has a current market capitalization of USD 12.3 bn and approximately USD 316.4 mn worth of Tempus Ai was traded on exchanges in the last 24 hours. Since last month end, Tempus Ai has traded -17.78 % down. Simple moving average of last 200 days is at USD 56.81. The highest price of past 52 weeks was recorded at USD 92 on 10/28/2025. 52 weeks low was at USD 40.77 on 07/28/2026.
Here is how related stocks have performed in the past 24 hours:
Neurocrine Biosciences (NBIX) traded down -0.41 % and now trades at USD 144.42. Neurocrine Biosciences has a market capitalisation of USD 14.5 bn. Neurocrine Biosciences has a current price to earnings ratio of 20.83.
Godaddy (GDDY) traded down -1.69 % and now trades at USD 111.97. Current market capitalisation for Godaddy is USD 14.3 bn. Godaddy has a current price to earnings ratio of 16.74.
Blue Owl Capital (OWL) traded down -3.6 % and now trades at USD 9.28. Current market capitalisation for Blue Owl Capital is USD 14.7 bn. Blue Owl Capital has a current price to earnings ratio of 79.04.
Solventum (SOLV) traded down -2.33 % and now trades at USD 87.14. Solventum has a market capitalisation of USD 14.5 bn. Solventum has a current price to earnings ratio of 9.3.
Halozyme Therapeutics (HALO) traded up 0.88 % and now trades at USD 127.35. Current market capitalisation for Halozyme Therapeutics is USD 14.3 bn. Current price/earnings ratio for Halozyme Therapeutics is 37.28. Johnson & Johnson’s experimental combination, RYBREVANT FASPRO, has reported encouraging early‑stage results in first‑line treatment of advanced head‑and‑neck squamous cell carcinoma. In the Phase 1b/2 OrigAMI‑4 Cohort 5 study, patients receiving the subcutaneous bispecific antibody with a PD‑1 inhibitor and carboplatin achieved a high rate of tumour shrinkage, with most responses occurring within nine weeks and remaining durable at a median follow‑up of over ten months. The regimen showed particular activity in non‑HPV‑associated disease, where complete remissions were observed in a notable fraction of patients. Safety data were consistent with the known profiles of the individual agents, with common adverse events including anaemia, hypoalbuminaemia and stomatitis. The company has also submitted a Priority Review application for later‑line use and continues to evaluate the therapy in a pivotal Phase 3 study, indicating a sustained research focus on expanding treatment options for this aggressive cancer type.
